True North Advisors LLC Makes New Investment in IDEXX Laboratories, Inc. $IDXX

True North Advisors LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,411 shares of the company’s stock, valued at approximately $793,000.

A number of other hedge funds have also modified their holdings of IDXX. Harbour Investments Inc. boosted its position in IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after acquiring an additional 16 shares during the last quarter. CWA Asset Management Group LLC grew its stake in IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after acquiring an additional 17 shares in the last quarter. Rockland Trust Co. grew its stake in IDEXX Laboratories by 4.4% during the 4th quarter. Rockland Trust Co. now owns 425 shares of the company’s stock valued at $288,000 after acquiring an additional 18 shares in the last quarter. Prime Capital Investment Advisors LLC raised its holdings in IDEXX Laboratories by 0.5% in the 4th quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock valued at $2,654,000 after acquiring an additional 18 shares during the last quarter. Finally, Pinnacle Associates Ltd. raised its holdings in IDEXX Laboratories by 1.5% in the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock valued at $830,000 after acquiring an additional 18 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of research reports. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $567.44 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $513.02 and a 12-month high of $769.98. The stock has a market cap of $44.76 billion, a P/E ratio of 41.78, a PEG ratio of 3.10 and a beta of 1.55. The company has a 50-day moving average price of $554.49 and a 200 day moving average price of $599.94. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.